Inclusion Criteria:

          1. Relapsed/refractory (R/R) previously treated B cell malignancies.

          2. Prior treatment must include at least 2 prior regimens, including anti CD20 antibody
             therapies.

          3. Documented measurable disease as defined by Lugano 2014

          4. Male or female ≥ 18 years of age

          5. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1

          6. Adequate hematological, renal, pulmonary, cardiac, and liver function

          7. Resolved toxicities of any prior therapy to either baseline or CTCAE grade 1 (version
             5.0)

          8. Female patients who are not pregnant or breastfeeding

          9. Female patients of childbearing potential and all male patients must agree to use
             highly effective methods of birth control for the duration of the study.

        Exclusion Criteria:

          1. Known CD20-negative B cell lymphoma at time of initial diagnosis

          2. Current or history of any of the following conditions:

               1. Central nervous system (CNS) primary lymphoma (current or history)

               2. Unrelated malignancy requiring systemic treatment (current or history [in the
                  past 3 years, other than hormonal treatment which is allowed])

          3. Any of the following current conditions:

               1. Active acute or chronic graft versus host disease (GvHD) other than grade 1 with
                  skin involvement, or GvHD requiring immunosuppressive treatment within 4 weeks of
                  enrollment

               2. Any other acute or chronic medical or psychiatric condition that may increase the
                  risk associated with study participation or investigational product
                  administration

               3. Tumor mass effects such as bowel obstruction or blood vessel compression that
                  require therapy

               4. Opportunistic infections

          4. History of any clinically significant conditions in the opinion of the Investigator,
             including, but not limited to:

               1. Infection (including sepsis, pneumonia, bacteremia, fungal, viral and
                  opportunistic infections) within 4 weeks prior to first dose of ADI 001

               2. Any form of primary immunodeficiency such as severe combined immunodeficiency
                  disease

               3. Cardiovascular conditions (Class III or IV heart failure as defined by the New
                  York Heart Association [NYHA], cardiac angioplasty or stenting, myocardial
                  infarction, unstable angina, or other clinically significant cardiac disease)
                  within the past 6 months

               4. Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura
                  within the 4 weeks prior to first dose of ADI 001 or the need for daily
                  prednisone greater than 5 mg (or corticosteroid equivalent) to control an
                  autoimmune disease

               5. Severe immediate hypersensitivity reaction to any of the agents used in this
                  study

          5. Prior treatment with any of the following:

             a Gene therapy, genetically modified cell therapy, or adoptive T cell therapy within 6
             weeks of study enrollment. Exception: Prior therapy with approved anti-CD19 CAR T cell
             products is allowed.

             b Radiation therapy within 4 weeks prior to study entry. Palliative local radiation
             may be allowed within 1 week prior to study entry.

             c Autologous stem cell transplant (SCT) within 6 weeks of planned ADI 001 infusion d
             Allogeneic stem cell transplant and donor lymphocyte infusion within 3 months of
             planned CAR T cell infusion

          6. Patients unwilling to participate in an extended safety monitoring period (long term
             follow up [LTFU] protocol)